Sunday, September 30, 2012

Merck Is The ONE To Watch- Buyout Written On The Wall For Peregrine Pharmaceuticals (PPHM) believes Sierra World Equity Review

Sierra and the team now believe that Merck is the one to watch in any potential acquisition of Peregrine Pharmaceuticals (PPHM) after it's disastrous PPS collapse following company revelations to it's shareholders that incompetence by an "independent third-party" lead to the previous positive mid-stage Bavituximab trials being discounted.
Accurate and independent Sierra World Equity Review made more more correct calls in the last 2 months than all other Stock Reviews COMBINED. Sierra always provides FREE, independent insight for her readers.....ARE YOU a BELIEVER YET!! Check back for updates....Sierra World Equity Review currently hold no positions in any of the companies mentioned in this report.....be the first to read our new posts follow us on Twitter at https://twitter.com/#!/SierraEquity

Southridge Enterprises (SRGE) To Continue Rising on Monday- Chart and Comments From Sierra World Equity Review

Sierra World Equity Review presents the latest Daily Chart of Southridge Enterprises (SRGE). After accurate Sierra analysed the chart she forecasts a GREEN MONDAY coming up for SRGE. From a technical standpoint Sierra says that the WilliamsPercentR, MoneyFlowIndex and Momentum technical indicators are SCREAMING that this stock is moving up on Monday October 1st, 2012. Added to the recent press release by the company of an increase to their stock buyback program things look good this week for the shareholders says Sierra. Remember Sierra told you this FIRST! Accurate and independent Sierra World Equity Review made more more correct calls in the last 2 months than all other Stock Reviews COMBINED. Sierra always provides FREE, independent insight for her readers.....ARE YOU a BELIEVER YET!! Check back for updates....Sierra World Equity Review currently hold no positions in any of the companies mentioned in this report.....be the first to read our new posts follow us on Twitter at https://twitter.com/#!/SierraEquity


Rising Star Rosetta Genomics (ROSG) Top Buyout Candidate Ventures Sierra World Equity Review

Accurate and independent Sierra World Equity Review really likes Rosetta Genomics (ROSG), Sierra and her team now project that ROSG is a top flight candidate in the very busy bio tech acquisition market. With patents and potential massive revenues ROSG is looking very attractive to some of the larger pharmaceutical companies who face declining revenues from expiring patents and slow production pipelines. Sierra ventures that ROSG had thrust itself into the spotlight and says to watch for official PR's in the weeks ahead signalling that something may be going on behind the scenes. Accurate and independent Sierra World Equity Review made more more correct calls in the last 2 months than all other Stock Reviews COMBINED. Sierra always provides FREE, independent insight for her readers.....ARE YOU a BELIEVER YET....Remember Sierra told you first!  Check back for updates....Sierra World Equity Review currently hold no positions in any of the companies mentioned in this report.....be the first to read our new posts follow us on Twitter at https://twitter.com/#!/SierraEquity

Bidding War IS VERY GOOD For Great Basin Gold (GBG)-Stock To Bounce When Trading Resumes Ventures Sierra World Equity Review

Sierra World Equity Review believes there is light at the end of the tunnel for shareholders of Great Basin Gold (GBG). It appears that a bidding war between multiple parties may be in the offering after AngloGold Ashanti (AU) got a little hamstrung by wildcat strikes at it's South African properties. With the door open Sierra says watch for this very positive development as a bidding war will improve GBG's position, Sierra also predicts that when trading resumes it will likely be on the OTC but JUST WATCH GBG BOUNCE! Accurate and independent Sierra World Equity Review made more more correct calls in the last 2 months than all other Stock Reviews COMBINED. Sierra World Equity Review currently hold no positions in any of the companies mentioned in this report.....be the first to read our new posts follow us on Twitter at https://twitter.com/#!/SierraEquity

Saturday, September 29, 2012

Global Technologies (GTGP) To Clear Financials With SEC, Will Resume Trading Ventures Sierra World Equity Review

Sierra World Equity Review empathizes with the shareholders of Global Technologies (GTGP) who suddenly found themselves in a stock that trading was suddenly halted by the SEC. Sierra believes that unlike many of the other dubious stocks also suspended, GTGP will get it's act together and correct it's financials which appear to be the sole (and legitimate) reason for the SEC to temporarily suspend trading. Sierra believes this is not only a wake up call to management but also an opportunity to clear the financials and never have to look back! Accurate and independent Sierra World Equity Review made more more correct calls in the last 2 months than all other Stock Reviews COMBINED. Sierra always provides FREE, independent insightfor her readers.....ARE YOU a BELIEVER YET....Remember Sierra told you first!  Check back for updates....Sierra World Equity Review currently hold no positions in any of the companies mentioned in this report.....be the first to read our new posts follow us on Twitter at https://twitter.com/#!/SierraEquity

Santo Mining (SANP) To Fall HARD This Week Predicts Accurate Phenom Sierra of Sierra World Equity Review

Sierra World Equity Review applauds all those who were able to profit from playing Santo Mining (SANP) on last Friday when it rose over 88%. Sierra believes that a heavily promoted stock like SANP will now turn and Sierra cautions all shareholders to take your profits and DO NOT GET BURNED when this plummets.
Remember you heard it FIRST here...accurate and independent Sierra World Equity Review made more more correct calls in the last 2 months than all other Stock Reviews COMBINED. Sierra always provides FREE, independent insight for her readers.....ARE YOU a BELIEVER YET....Remember Sierra told you first!  Check back for updates....Sierra World Equity Review currently hold no positions in Santo Mining (SANP).....be the first to read our new posts follow us on Twitter at https://twitter.com/#!/SierraEquity

WARNING!! Shorts BEWARE!! _Rosetta Genomics (ROSG) Set to Break OUT Next Week-Massive WEEK AHEAD for Rosetta - Sierra World Equity Review

Accurate and independent Sierra World Equity Review has GREAT news for all the longs holding Rosetta Genomics (ROSG). This coming week is going to be HUGE for ROSG, Sierra is not only predicting a huge run as the stock breaks out but added impetus will fuel the run as Sierra believes a MAJOR POSITIVE new news piece on ROSG is coming. Accurate Sierra predicted the last great run for ROSG here is that piece with the link:

"On Sunday 09/16/2012 accurate and independent Sierra made the call that Rosetta Genomics (ROSG) was going to start surging forward starting today. Today ROSG rose 0.92 cents (17.42%) at the closing bell and then moved up an additional 0.16 cents (2.58%) in after hours trading. Time after time Sierra proves how ACCURATE she is....here is the proof, the link to yesterdays prediction by Sierra:
Yet another GREAT call by Sierra on Rosetta Genomics (ROSG)"
 
Accurate and independent Sierra World Equity Review made more more correct calls in the last 2 months than all other Stock Reviews COMBINED. Sierra always provides FREE, independent insight for her readers.....ARE YOU a BELIEVER YET....Remember Sierra told you first!  Check back for updates....Sierra World Equity Review currently hold no positions in any of the companies mentioned in this report.....be the first to read our new posts follow us on Twitter at https://twitter.com/#!/SierraEquity

Friday, September 28, 2012

Last Minute Pre-Trial Settlement Coming From Google (GOOG) -MASSIVE SETTLEMENT For Vringo (VRNG)- Ventures Sierra World Equity Review

Sierra World Equity Review is now projecting that a last minute pre-trial settlement is coming from Google (GOOG) to resolve the patent lawsuit with Vringo (VRNG). Sierra and the team now believe that Google have a MASSIVE settlement in the works and are preparing to present it to VRNG to resolve this case. Sierra believes that shareholders of VRNG should not have any trouble sleeping at night, they are about to hit the JACKPOT! Accurate and independent Sierra World Equity Review made more more correct calls in the last 2 months than all other Stock Reviews COMBINED. Sierra World Equity Review currently hold no positions in VRNG or GOOG ......be the first to read our new posts follow us on Twitter at  https://twitter.com/#!/SierraEquity

Will Sanofi (SNY) Move on Weakened Questcor Pharmaceuticals (QCOR)? Brave Face Today from QCOR ventures Sierra World Equity Review

Today the PPS of Questcor Pharmaceuticals (QCOR) was up over 3% on news that QCOR plans to initiate a .20 cent per share dividend AND also double it's share repurchase authorization. Sierra World Equity Review believes that this is simply a brave face being put on by a company that is under intense pressure. Sierra believes that French Pharmaceutical giant Sanofi (SNY) may make a play for QCOR. Sierra and the team are closely monitoring this situation....accurate and independent Sierra World Equity Review made more more correct calls in the last 2 months than all other Stock Reviews COMBINED. Sierra World Equity Review currently hold no positions in QCOR or Sanofi (SNY) ......be the first to read our new posts follow us on Twitter at  https://twitter.com/#!/SierraEquity

BUYOUT Coming for Peregrine Pharmaceuticals (PPHM) believes Sierra World Equity Review- Sierra TOLD YOU FIRST!!

Peregrine Pharmaceuticals (PPHM) fell another 7% today. Sierra World Equity Review is now predicting a BOUNCE as institutional investors hop on board realizing that a potential BUYOUT is highly probable. Will it be Roche or Merck, Sierra forecasts that it will be one of these 2 big players. Remember you heard it here FIRST. Accurate and independent Sierra World Equity Review......Sierra World Equity Review currently hold no positions in Peregrine Pharmaceuticals, Roche or Merck.....be the first to read our new posts follow us on Twitter at https://twitter.com/#!/SierraEquity

Thursday, September 27, 2012

Is Today's Google (GOOG) US Patent Action Part of the SETTLEMENT or BUYOUT DANCE with Vringo (VRNG)? ventures Sierra World Equity Review

As the patent trial date quickly approaches Sierra World Equity Review believes we will see quite a bit of legal maneuvering, Sierra is of the opinion that this could all be part of the "BUYOUT DANCE" as Google looks to potentially settle with VRNG or simply acquire the company to resolve all issues. Any acquisition or settlement by Google will be massive for VRNG and it's shareholders. Accurate and independent Sierra World Equity Review made more more correct calls in the last 2 months than all other Stock Reviews COMBINED. Sierra World Equity Review currently hold no positions in VRNG or GOOG ......be the first to read our new posts follow us on Twitter at  https://twitter.com/#!/SierraEquity
Sierra is currently on the ground in Singapore to try to meet talented Xiaxue aka Wendy Cheng Yan Yan to recruit her to the Sierra World Equity Review awesome team.


7 DAYS Or Less -Very Positive News Coming For Star Scientific (STSI)- believes Sierra World Equity Review-Sierra Told You FIRST!

Accurate and independent is predicting that within the NEXT 7 DAYS or LESS more very GOOD news will be coming for Star Scientific (STSI). Just you wait and see says Sierra, accurate and independent Sierra World Equity Review made more more correct calls in the last 2 months than all other Stock Reviews COMBINED. Sierra World Equity Review currently hold no positions in Star Scientific (STSI)  .....be the first to read our new posts follow us on Twitter at https://twitter.com/#!/SierraEquity
Sierra is currently on the ground in Singapore to try to meet talented Xiaxue aka Wendy Cheng Yan Yan to recruit her to the Sierra World Equity Review awesome team.


Will It Be Roche Or Merck? Another Bad Day For Peregrine Pharmaceuticals (PPHM) Brings It Another Step Closer To Acquisition ventures Sierra World Equity Review

After announcing today that it had defaulted on a $30 million loan agreement Peregrine Pharmaceuticals (PPHM) shareholders had another rough day as the PPS plummeted over 33% at the closing bell. Sierra World Equity Review firmly believes that PPHM is going to get scooped up by a larger player in the pharmaceutical industry, Sierra believes it may come down to a bidding war between Roche Or Merck....Sierra's opinion that this potential buyout could be coming SOONER than LATERRemember you heard it here FIRST. 
Follow Sierra on Twitter To Get The Next PUBLISHER ALERT~~Follow Sierra on Twitter

Wednesday June 4th 2014
Special ALERT From The Office Of The Publisher Of Sierra World Equity Review 

Proteo (PTEO)

Highlights:

Welcome, our latest Publisher Alert is Proteo (PTEO) with ORPHAN drug status granted for for it's lead drug Tiprelestat (Elafin) BOTH in the European Union AND the United States

(Orphan drug status is a VERY GOOD status to receive, Proteo (PTEO) received it on BOTH continents from the FDA and their European counterparts the EMA)

On May 20th 2014, Proteo (PTEO) signed an agreement with Biotech Development Corp. (BDC) who gave them total funds of EURO 3.5 million (approx. US$ 4.8 million) in return for a share of future revenues for Tiprelestat (Elafin).


(Wow, you only ante up that kind of money if you are VERY CONFIDENT APPROVAL for drug is coming!) 

In February 2014, Proteo (PTEO) received Protocol Assistance (scientific advice for orphan medicines) from the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) with respect to the strategy for further clinical development and marketing authorization for Tiprelestat (Elafin) 

(There's the answer, the European Medicines Agency (EMA) is taking them under their wing and helping guide them toward APPROVAL. No wonder Biotech Development Corp. was eager to ink a multi million dollar deal with Proteo!!!....It really helps when the regulatory agency helps walk you through the process toward APPROVAL. Remember this company is ONLY going to invest all those millions if they believe that APPROVAL from the EMA is coming, they invested and for the rest of us that is a HUGE BUY SIGNAL!!)

With a LOW FLOAT of just 11.4 Million shares Proteo (PTEO) is under the radar and the share price is likely to move up quickly as news of the company spreads.

Amazingly the share price of Proteo (PTEO) at the close of Friday's session on May 30th 2014 was just .09 cents, the positive news has not yet caught up with the share price, BUT IT WILL, now is the time to BUY Proteo (PTEO) BEFORE the share price takes off!!

More info and WHY Sierra's Publisher has initiated a long position in Proteo (PTEO) with information taken from the company's website, SEC filings and recent official press releases.

With over 1 million visitors to our blog and sites and thousands of visitors daily Sierra World Equity Review will be giving MASSIVE MULTIPLE DAY targeted audience exposure to Proteo (PTEO) the share price is only going to rise!

Proteo (PTEO) through it's wholly owned subsidiary, Proteo Biotech AG, that is a German corporation is a clinical stage biotech drug development company focusing on the development of anti-inflammatory treatments for rare diseases with significant unmet needsProteo (PTEO) intends to develop, promote and market pharmaceuticals and other biotech products.

Proteo (PTEO) lead product is Tiprelestat (Elafin) that prevents acute postoperative inflammatory complications. Tiprelestat (Elafin) ability to block the proteases that cause these undesirable effects makes it a promising drug for the treatment of various inflammatory diseases and post traumatic inflammatory complications

Currently Tiprelestat (Elafin) is undergoing clinical trials for 3, yes..THREE different diseases:

Esophagus cancer surgery (Phase II completed, Phase III planning)
Coronary artery bypass surgery (Phase II ongoing)
Kidney transplantation (Phase II regulatory approval)

The excellent tolerability of Tiprelestat (Elafin) in human subjects has led to late stage clinical trials.

BUT IT GETS EVEN BETTER:

Proteo (PTEO) and it's Orphan Drug Designation:

In the US and EU it is easier to gain marketing approval for an orphan drug, and there may be other financial incentives, such as tax credits and extended exclusivity periods for the drug, all intended to encourage the development of drugs which might otherwise not have been developed.
Orphan Drug Designation has been awarded to the Proteo (PTEO) by the European Commission for the use of Tiprelestat (Elafin) in the treatment of esophagus carcinoma

The U.S. Food and Drug Administration (FDA) has GRANTED orphan drug designation to Tiprelestat (Elafin) for the prevention of inflammatory complications of transthoracic esophagectomy AND for pulmonary arterial hypertension.

In February 2014, Proteo (PTEO) received Protocol Assistance (scientific advice for orphan medicines) from the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) with respect to the strategy for further clinical development and marketing authorization for Tiprelestat (Elafin) when used for acute postoperative inflammatory complications after resection of esophageal cancer. 
(Once again It really helps when the regulatory agency helps walk you through the process toward APPROVAL)

For the development of its lead product Tiprelestat (Elafin) Proteo (PTEO) has established a network of globally renowned research institutes, physicians and hospitals in the US and Europe. The development of Tiprelestat (Elafin) has been widely supported by public grants. Worldwide leading funding bodies, such as the American National Institutes of Health (NIH) and the British Medical Research Council (MRC), support preclinical and clinical studies on Tiprelestat (Elafin) with high volume grants
(Most biotechs would be VERY ENVIOUS to have so many grants and major organisations paying for the research and development of their leading drug!)

Follow Sierra on Twitter To Get The Next PUBLISHER ALERT~~Follow Sierra on Twitter

About Our Special Publisher ALERTS 
Sierra's Publisher CHERRY picks only the very best stocks for our Publisher Alerts, EVERY Publisher Alert so far has been a WINNER, Sierra's publisher is batting 100% thanks to the POWER OF EXPOSURE on Sierra World Equity Review.

During 2014, as a measure of appreciation to our readership, the publisher of Sierra World Equity Review has decided to give Sierra's loyal readers the heads up once or twice a week on stocks that he has taken a position in, they are flying low under the radar and that are on the verge of breaking out and potentially being a 10 bagger from when Sierra's Publisher issues the ALERT! 

About Sierra World Equity Review
Using complex proprietary algorithms in our price targets and ratings Sierra World Equity Review makes accurate calls! We now update our 10 day short term price targets and BUY or SELL ratings for each stock every 14 days. 

Sierra World Equity Review is also smoking hot in our predictions!! From FDA Drug Approvals and Trials to Potential Joint Ventures, Mergers, Buyouts, Acquisitions and Lawsuit Settlements..... get THE Scoop, always on the cutting edge of BIG Breaking News. Sierra World Equity Review covers all sectors from Biotech to Oil stocks, Gold stocks, Penny stocks on the OTC as well as the S&P, Nasdaq, Dow Jones and Amex. Sierra World Equity Review made more correct calls in the last 23 months than all other Stock Reviews COMBINED!! We have had excellent success but please remember to always do your own due diligence in regards to any stocks we feature! Good luck in all your trades! For the latest updates on these stocks follow Sierra on Twitter

Research In Motion (RIMM) To Soar on Friday_Big Things Coming says Sierra World Equity Review

Accurate and independent Sierra previously predicted on June 29th 2012, that RIMM would surprise doubters and was heading in the correct direction. Here is the link to that accurate prediction:
Sierra predicted good things for RIMM on June 29th 2012
Today RIMM proved Sierra correct....now Sierra believes even BIGGER things are ahead for the company and it's shareholders. Check back as Sierra prepares to be the FIRST with the good news...Accurate and independent Sierra World Equity Review made more more correct calls in the last 2 months than all other Stock Reviews COMBINED. Sierra World Equity Review currently hold no positions in Research In Motion (RIMM) .....be the first to read our new posts follow us on Twitter at https://twitter.com/#!/SierraEquity

Wednesday, September 26, 2012

Star Scientific (STSI) HEADING NORTH-Accurate and Independent Sierra World Equity Review Was Correct Again, More Big Positive News Coming says Sierra

Sierra World Equity Review correctly called Star Scientific (STSI) continued rise up over 14% today. Sierra  believes that yet more BIG POSITIVE news is coming to Star Scientific and it's shareholders. Check back for updates at anytime as Sierra prepares to be the FIRST to call this big news! Accurate and independent Sierra World Equity Review made more more correct calls in the last 2 months than all other Stock Reviews COMBINED. Sierra World Equity Review currently hold no positions in Star Scientific (STSI)  .....be the first to read our new posts follow us on Twitter at https://twitter.com/#!/SierraEquity
Sierra is currently en route to Singapore to try to meet talented Xiaxue aka Wendy Cheng Yan Yan to recruit her to the Sierra World Equity Review awesome team.

Under Pressure Will Questcor Pharmaceuticals (QCOR) Be Sold To Sanofi (SNY) Ventures Sierra World Equity Review

Sierra World Equity Review continues to monitor Questcor Pharmaceuticals (QCOR), today the stock had another bad day finishing down over 5 % and continued down in after hours trading. With a class action suit and investigations under way this stock is UNDER PRESSURE! Expect the PPS to continue falling says Sierra, also look for the weakening hand of QCOR to open the door for a larger player like French Pharmaceutical giant Sanofi (SNY) who may be on a potential short list of companies interested in purchasing a distressed QCOR. Check back for updates as Sierra and her team, Adam, Natasha and Johnny investigate this potential possibility. Accurate and independent Sierra World Equity Review made more more correct calls in the last 2 months than all other Stock Reviews COMBINED. Sierra World Equity Review currently hold no positions in QCOR or Sanofi (SNY) ......be the first to read our new posts follow us on Twitter at  https://twitter.com/#!/SierraEquity
Sierra is currently en route to Singapore to try to meet talented Xiaxue aka Wendy Cheng Yan Yan to recruit her to the Sierra World Equity Review awesome team.


Life Partners (LPHI) to continue soaring predicts accurate Sierra World Equity Review after favorable court decision. Sierra initiates coverage of LPHI

Sierra World Equity Review has initiated coverage Life Partners (LPHI), Sierra believes the shareholders have seen nothing yet and predicts this stock will continue to soar. Check back for updates as Sierra and the team give intense coverage to LPHI. Sierra World Equity Review currently hold no positions in Peregrine Pharmaceuticals (PPHM).....be the first to read our new posts follow us on Twitter at https://twitter.com/#!/SierraEquity
Sierra is currently en route to Singapore to try to meet talented Xiaxue aka Wendy Cheng Yan Yan to recruit her to the Sierra World Equity Review awesome team.

Will Roche Rescue Peregrine Pharmaceuticals (PPHM)--Buyout Coming Soon ventures Sierra World Equity Review

After more negative news today regarding it's remaining operational capital after having repaid a loan, Peregrine Pharmaceuticals (PPHM) now says it can only fund it's operation thru April 2013. Sierra believes that the door is now open to PPHM being acquired by a larger player in the industry who Sierra thinks will be Roche. Remember you heard it here FIRST. Accurate and independent Sierra World Equity Review......Sierra World Equity Review currently hold no positions in Peregrine Pharmaceuticals (PPHM).....be the first to read our new posts follow us on Twitter at https://twitter.com/#!/SierraEquity
Sierra is en route to Singapore to try to meet talented Xiaxue aka Wendy Cheng Yan Yan to recruit her to the Sierra World Equity Review awesome team.

Sierra World Equity Review wants Xiaxue to join the team...Xiaxue will be a great addition says Sierra...c'mon Xiaxue our fans want Xiaxue!!

Sierra loves following Xiaxue on her blog, Sierra is flying to Singapore to try to sign up Xiaxue to be part of Sierra World Equity Review's team.  Xiaxue aka "My name is Wendy Cheng Yan Yan. I was born on 28th of April in 1984, to my Singaporean-Chinese parents in Singapore" is an avid blogger who inspired Sierra World Equity Review aka "Sierra" to blog. Xiaxue means snowing says Xiaxue.
What an amazing addition to the team Xiaxue would be, besides says Sierra..."she is very cute". Check back and see if Xiaxue joins the team.

Tuesday, September 25, 2012

Accurate Sierra World Equity Review Was The FIRST To Call The Mimvi (MIMV) & Microsoft (MSFT) Partnership Back on July 30th--Are You a Believer In Sierra Yet!!

Sierra World Equity Review is accurate and independent. Not to toot our own horn but just for the record Sierra way back on July 30th made the call that Mimvi (MIMV) & Microsoft (MSFT) were heading toward a partnership. Here is the link to Sierra's prediction back on July 30th, 2012:
Accurate Sierra's prediction of MSFT & MIMV Partnership
Today, September 25th the parties announced a partnership and MIMV soared over 111%. Sierra is delighted for shareholders of MIMV and she believes the PPS is going to keep going up. Check back for updates as Sierra and the team follow MIMV for new developments. Accurate and independent Sierra World Equity Review made more more correct calls in the last 2 months than all other Stock Reviews COMBINED. Sierra World Equity Review currently hold no positions in MIMV or MSFT ......be the first to read our new posts follow us on Twitter at  https://twitter.com/#!/SierraEquity

Just Days On A Calender Now_A Google (GOOG) Resolution To Patent Case To Change The Lives of Vringo (VRNG) And It's Shareholders ventures Sierra World Equity Review

All Vringo (VRNG) shareholders should be closely watching the news over the next few days, at anytime a resolution to the patent trial between Google (GOOG) and VRNG could be announced. In Sierra's opinion the PPS of VRNG is going to keep moving up as each day passes. Sierra believes that VRNG may offer up 30-50 million shares to institutional buyers to raise their cash strength applying pressure to GOOG and giving the company leverage as the trial date gets close, such a move might cause the PPS of VRNG to drop but this will only be temporary says Sierra. Any acquisition or settlement by Google will be massive for VRNG and it's shareholders. Accurate and independent Sierra World Equity Review made more more correct calls in the last 2 months than all other Stock Reviews COMBINED. Sierra World Equity Review currently hold no positions in VRNG or GOOG ......be the first to read our new posts follow us on Twitter at  https://twitter.com/#!/SierraEquity


Peregrine Pharmaceuticals (PPHM) and Roche, PPHM Rebounds up 46.57% -Sierra Correctly Called Today's Green Day

Accurate and independent Sierra World Equity Review correctly called today's rebound...here is the link to what Sierra said yesterday:

Sierra believes that PPHM will continue to edge back up to it's former levels and is confidant that Bavi trials will eventually be positive and ultimately get approved by the FDA. Sierra also continues to believe that Roche or another larger player in the pharmaceutical industry may try to move on PPHM more so now than ever after it's recent setback.
Remember you heard it here FIRST. Accurate and independent Sierra World Equity Review......Sierra World Equity Review currently hold no positions in Peregrine Pharmaceuticals (PPHM).....be the first to read our new posts follow us on Twitter at https://twitter.com/#!/SierraEquity

Monday, September 24, 2012

Star Scientific (STSI) To Surge Following Settlement of Patent Suit with RJ Reynolds--Sierra World Equity Review

Sierra World Equity Review is predicting that Star Scientific (STSI) will start moving up sharply now after the announcement of an apparent settlement of it's patent suit with RJ Reynolds. Sierra believes shareholders of STSI are in for a very nice surprise, in Sierra's opinion  STSI may have received a significant financial settlement. Accurate and independent Sierra World Equity Review made more more correct calls in the last 2 months than all other Stock Reviews COMBINED. Sierra World Equity Review currently hold no positions in Star Scientific (STSI)  .....be the first to read our new posts follow us on Twitter at https://twitter.com/#!/SierraEquity


10 Days or Less-AngloGold Ashanti (AU) To Tend Offer To Great Basin Gold (GBG) ventures Sierra World Equity Review

Sierra World Equity Review has been closely following developments in South Africa regarding Great Basin Gold (GBG) and it's Burnstone mine. Sierra is predicting that WITHIN THE NEXT 10 DAYS executives at AngloGold Ashanti (AU) will make their proposal to either partner up or acquire the Burnstone mine from GBG. Remember you heard it FIRST here from Sierra! Sierra believes It has been very hectic as AU is doing a balancing act trying to resolve and minimize wildcat strikes that could endanger company revenues while still focusing on a potential deal with GBG. Accurate and independent Sierra World Equity Review made more more correct calls in the last 2 months than all other Stock Reviews COMBINED. Sierra World Equity Review currently hold no positions in any of the companies mentioned in this report.....be the first to read our new posts follow us on Twitter at https://twitter.com/#!/SierraEquity


Is Questcor Pharmaceuticals (QCOR) "Damaged Goods", Will a Buy Out Now Be On The Horizon ventures Sierra World Equity Review

After taking a beating thanks to the announcement of a government inquiry, Questcor Pharmaceuticals (QCOR) looks set to continue to plummet after being downgraded by multiple ratings firms. Sierra and her team are now closely monitoring any potential activity by a larger player in the pharmaceutical industry who may be interested in leveraging the plight of QCOR to their advantage in a possible acquisition that might be the saving grace to the shareholders of QCOR. Sierra and the team have their ears to the ground and will update asap....check back for updates. Accurate and independent Sierra World Equity Review made more more correct calls in the last 2 months than all other Stock Reviews COMBINED. Sierra World Equity Review currently hold no positions in QCOR......be the first to read our new posts follow us on Twitter at  https://twitter.com/#!/SierraEquity

Peregrine Pharmaceuticals (PPHM) WILL REBOUND After Shocking Incompetence by "independent third-party" - Bavituximab trials WILL Ultimately Prove POSITIVE- Just You Wait And See - Sierra World Equity Review

Sierra World Equity Review empathizes with the anger of Peregrine Pharmaceuticals (PPHM)
shareholders who were totally blindsided by the revelation today that incompetence by an "independent third-party" lead to the previous positive mid-stage Bavituximab trials being discounted.
Sierra believes that PPHM will rebound and that this setback will be temporary and if anything should be seen as a buying opportunity. Sierra continues to believe that Bavi will ultimately get approved by the FDA despite this setback, once the dust settles PPHM is going to move back up...JUST YOU WAIT AND SEE says Sierra! Remember you heard it here FIRST. Accurate and independent Sierra World Equity Review......Sierra World Equity Review currently hold no positions in Peregrine Pharmaceuticals (PPHM).....be the first to read our new posts follow us on Twitter at https://twitter.com/#!/SierraEquity 


Sunday, September 23, 2012

BULLETPROOF--Lorcaserin To Be APPROVED By European Medicines Agency Believes Accurate Sierra World Equity Review

Following an apparent setback for Vivus (VVUS) in trying to get approval for their obesity drug  Qsymia, concern has been voiced if the same fate might await Arena Pharmaceuticals (ARNA) lorcaserin (Belviq). Sierra remains UNEQUIVOCAL in her opinion that shareholders of ARNA have nothing to be worried about, APPROVAL in Europe for lorcaserin (Belviq) WILL HAPPEN! In fact says Sierra, with no competition from rival VVUS, ARNA shareholders should continue to see the PPS of the stock climb steadily upwards. Of course says Sierra, any announcement from Pfizer regarding a potential acquisition will just skyrocket the PPS. Accurate and independent Sierra World Equity Review made more correct calls in the last 2 months than all other Stock Reviews COMBINED. Sierra World Equity Review currently hold no positions in  Arena Pharmaceuticals (ARNA) or Vivus (VVUS) .....be the first to read our new posts follow us on Twitter at  https://twitter.com/#!/SierraEquity


Sierra Told You FIRST_Potential BUYOUT To Happen Early January 2013, Seagate (STX) To Acquire OCZ Technology (OCZ) believes Sierra World Equity Review

With the departure of OCZ Technology (OCZ) CEO Sierra says the writing is on the wall. Sierra re-iterates her belief that shareholders of OCZ will be rewarded when a potential BUYOUT occurs between Seagate (STX) and OCZ. Sierra believes it will occur in early January and as the year end approaches watch for the PPS of OCZ to move strongly upwards! Accurate and independent Sierra World Equity Review made more more correct calls in the last 2 months than all other Stock Reviews COMBINED. Sierra World Equity Review currently hold no positions in OCZ Technology or Seagate (STX) .....be the first to read our new posts follow us on Twitter at  https://twitter.com/#!/SierraEquity



Massive GREEN Week Ahead For Hemispherx BioPharma (HEB) predicts Accurate Sierra World Equity Review

Sierra World Equity Review is forecasting a HUGE GREEN week coming for Hemispherx BioPharma (HEB). Sierra says the new FDA Safety and Innovation Act (FDASIA) is really going to work in the favor of HEB and it's shareholders. Sierra is making ANOTHER of her UNEQUIVOCAL ACCURATE FDA calls....Ampligen, a chronic fatigue syndrome drug will be APPROVED by the FDA. In the run up to FDA approval this stock is moving up says Sierra. Accurate and independent Sierra World Equity Review made more more correct calls in the last 2 months than all other Stock Reviews COMBINED. 
Sierra World Equity Review currently hold no positions in  Hemispherx BioPharma (HEB)   .....be the first to read our new posts follow us on Twitter at  https://twitter.com/#!/SierraEquity

Roche and Peregrine Pharmaceuticals (PPHM) Just You Wait, Sierra World Equity Review Predicted This FIRST!

Big couple of weeks ahead for Peregrine Pharmaceuticals (PPHM) says Sierra, on Tuesday Sierra believes that Roche and PPHM may be meeting in Geneva regarding a potential joint venture, Sierra and her team of Natasha, Adam and Johnny are closely monitoring PPHM for any breaking developments. Sierra now also ventures that the may not be the the FIRST meeting between the parties but may be a continuation of prior meetings. Look for BIG NEWS from any upcoming official PR's says Sierra.
Accurate Sierra also CORRECTLY predicted the following:
Accurate Sierra is also making the call that POSITIVE news will be released on a mid-stage study of PPHM's cancer drug bavituximab on September 7th

Remember you heard it here FIRST. Accurate and independent Sierra World Equity Review......Sierra World Equity Review currently hold no positions in any of the companies mentioned in this report.....be the first to read our new posts follow us on Twitter at https://twitter.com/#!/SierraEquity



Saturday, September 22, 2012

Nkomo Gives Thumbs Up on AngloGold Ashanti (AU) and Great Basin Gold (GBG) Burnstone Potential Joint Venture, AngloGold Ashanti Feverishly Working To Resolve Labor Strikes

Sierra World Equity Review is on the ground in South Africa! Sierra held a meeting today with Simon Nkomo who is well connected in this sector, afterwards Sierra told her team that he gave the "thumbs up" to a potential partnership between AngloGold Ashanti (AU) and Great Basin Gold (GBG) regarding the Burnstone mine. Simon Nkomo said that a 80/20 split would be the most probable outcome with the 80 going to AU and GBG getting the 20. Sierra is of the opinion that while GBG may only get 20% it certainly is a lot better than nothing and actually amounts to a substantial revenue stream as the Burnstone mine has massive untapped resources. Simon Nkomo also told Sierra that AU were very concerned about the wildcat strikes and were working feverishly behind the scenes with strike leaders to expedite a resolution.
Sierra is flying to Durban on the coast tomorrow and will be doing a photo shoot on Addington Beach as part of her modelling passion. Sierra plans to post some of her photo shoot pictures on her Twitter shortly. Accurate and independent Sierra World Equity Review made more more correct calls in the last 2 months than all other Stock Reviews COMBINED. Sierra World Equity Review currently hold no positions in any of the companies mentioned in this report.....be the first to read our new posts follow us on Twitter at https://twitter.com/#!/SierraEquity


Timeline Now In Place Google (GOOG) will Acquire Vringo (VRNG) by October 12, 2012 believes Sierra World Equity Review

Just WATCH and SEE how accurate Sierra World Equity Review is! Sierra now believes that by October 12th 2012 Google (GOOG) will have announced their intention to acquire Vringo (VRNG) and resolve the parties upcoming patent trial. Sierra also forecasts that the PPS of VRNG is going to move sharply upwards between now and October 12th, 2012. When all this comes to pass Sierra says the shareholders of VRNG will be smiling from ear to ear and those that are shorting the stock best be very careful not to get trapped.Accurate and independent Sierra World Equity Review made more more correct calls in the last 2 months than all other Stock Reviews COMBINED. 
Special ALERT From The Office Of The Publisher Of Sierra World Equity Review 

Sierra's NEW Publisher ALERT # 11 To Be Announced Thursday Night April 10th 2014.


Special ALERT From The Office Of The Publisher Of Sierra World Equity Review 

With over 1 million visitors to our blog and sites and thousands of visitors daily Sierra World Equity Review will be giving massive daily targeted 
audience exposure to our NEW PUBLISHER ALERT # 11, the share price is only going to explode upwards predicts Sierra World Equity Review. 

What a great way to start off our new series of Publisher ALERTS,  showing the POWER OF EXPOSURE on Sierra World Equity Review.


-Sierra's Publisher ALERT # 1 Vystar Corporation (VYST) had gains over 100%

-Sierra's Publisher ALERT # 2 Vista International Technologies (VVIT) had gains over 100% 
-Sierra's Publisher ALERT # 3 VeriTeQ Corporation (VTEQ) had gains over 30% 
-Sierra's Publisher ALERT # 4_Dolphin Digital Media (DPDM) surged over 55%
-Sierra's Publisher ALERT # 5_Powerdyne International  (PWDY) ran up over 37% 
-Sierra's Publisher ALERT # 6_The Digital Development Group (DIDG) ran up over 32%
-Sierra's Publisher ALERT # 7_AJ Greentech Holdings (AJGH) ran up over 35%
-Sierra's Publisher ALERT # 8 On The Move Systems (OMVS) soared almost 50% 
-Sierra's Publisher ALERT # 9 Broadview Institute (BVII) quick gains of over 31%
-Sierra's Publisher ALERT # 10 Global Water Technologies (GWTR)_rose over 40%

With over 1 million visitors to our blog and sites and thousands of visitors daily Sierra World Equity Review will be giving massive daily targeted audience exposure to our NEW PUBLISHER ALERT # 11, the share price is only going to explode upwards predicts Sierra World Equity Review. 

About Our Special Publisher ALERTS 
As a measure of appreciation to our readership, the publisher of Sierra World Equity Review has decided to give Sierra's loyal readers the heads up once or twice a week on stocks that he has taken a position in, they are flying low under the radar and that are on the verge of breaking out and potentially being a 10 bagger from when Sierra's Publisher issues the ALERT! 

Using complex proprietary algorithms in our price targets and ratings Sierra World Equity Review makes accurate calls! We now update our 10 day short term price targets and BUY or SELL ratings for each stock every 14 days. 

Sierra World Equity Review is also smoking hot in our predictions!! From FDA Drug Approvals and Trials to Potential Joint Ventures, Mergers, Buyouts, Acquisitions and Lawsuit Settlements..... get THE Scoop, always on the cutting edge of BIG Breaking News. Sierra World Equity Review covers all sectors from Biotech to Oil stocks, Gold stocks, Penny stocks on the OTC as well as the S&P, Nasdaq, Dow Jones and Amex. Sierra World Equity Review made more correct calls in the last 21 months than all other Stock Reviews COMBINED!! We have had excellent success but please remember to always do your own due diligence in regards to any stocks we feature! Good luck in all your trades! For the latest updates on these stocks follow Sierra on Twitter

Friday, September 21, 2012

Hemispherx BioPharma (HEB) Sierra World Equity Review Initiates Coverage Issues BUY Rating



Sierra World Equity Review has initiated coverage of 
Hemispherx BioPharma (HEB), Sierra has issued a BUY Rating for HEB...Sierra believes that HEB will get FDA approval for Ampligen, a chronic fatigue syndrome drug. Just watch as HEB continues to rise in the lead up to FDA approval ventures Sierra.
Known for her accurate forecasts and predictions especially in the bio-tech sector Sierra World Equity Review will be featuring several articles about Hemispherx BioPharma over the course of the next week. 
Sierra World Equity Review will be posting breaking new articles and frequent updates as Sierra focuses intense coverage on this stock. Sierra World Equity Review is independent, accurate and best of all FREE, recently Sierra was the only Stock Review who called correctly TWO different FDA recent bio-tech drug decisions, in fact Sierra called them unequivocally and days in advance...here's the proof: Sierra called it correctly days in advance for two obesity drugs under consideration by the FDA, the FDA had not given it's approval for over 12 years to any obesity drugs yet Sierra World Equity Review bucked the consensus and was CORRECT when when Belviq from Arena Pharmaceuticals was approved by the FDA and also CORRECTLY that Qnexa (Qsymia) from Vivus would be approved by the FDA (just look at the links below for proof!!). Repeating, we are VERY ACCURATE in our predictions and targets.
links to FDA predictions:
published June 26 2012 - Arena and Lorcaserin
If that is not stellar enough, independent and accurate Sierra also reminds her readers that on Tuesday September 4th 2012, Sierra World Equity Review made the unequivocal call that POSITIVE news will be released on a mid-stage study of PPHM's cancer drug bavituximab today. Here is the link to that ACCURATE prediction:
Sierra as usual was ACCURATE and spot on...the PPS of PPHM soared over 46% at the closing bell.
Sierra World Equity Review ALSO made more more correct calls in the last 2 months than all other Stock Reviews COMBINED....follow Sierra and let her make you a believer!

Sierra World Equity Review hopes you will enjoy our articles about   Hemispherx BioPharma (HEB), prosper and even join Sierra at one of her stock parties...Sierra will tell you when and where......Sierra World Equity Review currently hold no positions in  Hemispherx BioPharma (HEB)   .....be the first to read our new posts follow us on Twitter at  https://twitter.com/#!/SierraEquity